Valbiotis Publishes Interim Financial Results, Confirms Growth Path

Valbiotis, a French laboratory specializing in dietary supplements, unveiled its interim financial results, indicating a robust commercialization strategy. As of June 30, the company maintained a cash position of €13.2M, securing funds for ongoing commercial expansion. Valbiotis has reinforced its product lineup, with new introductions aimed at cardiometabolic health.

In the first half of 2025, revenues rose to €332K, predominantly from recently launched products. Although operating expenses decreased by 36%, due to a strategic shift from R&D towards commercialization, the company recorded a net loss of €4.59M. Nonetheless, funding activities, including a capital increase, bolstered cash flow, projecting a financial runway through late 2026.

Looking ahead, Valbiotis plans to continue expanding its sales force and product offerings, while engaging with international partners. The company aims to achieve significant revenue milestones by 2027 and consolidate its market presence both domestically and globally by 2030.